Search Results Within Category "Skin Conditions"Search all categories
A prospective, observational cohort study to assess flares in participants with hidradenitis suppurativa
This is a questionnaire study to establish new ways to measure HS flares. Subjects and providers will each complete questionnaires at regularly occurring visits.
- Medical History and Demographics Review- Weekly Questionnaires- HS Skin Assessments
Up to $320
Active HS within 3 months of baseline
Reliable internet access on a phone or computer
Not fluent in English
Mental impairment that would prevent you from understanding and responding to questionnaires
A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of Higher Doses of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure
Phase 1, Double- Blind Study, 15 week study, Patch test and Vaccine Injection, Males/Females 18-65 years old with history of urushiol exposure. The rash or allergic contact dermatitis of poison ivy is recognized as occurring after the exposure to the urushiol oil which is found in the leaves of poison ivy, oak and sumac. Currently there is no preventative treatment for contact dermatitis. The purpose of this study is to find out if the vaccine, PDC-APB can help with the prevention of contact dermatitis.
Willing to follow all study instructions
Attend all study visits
Positive test result of HIV, Hepatitis B or Hepatitis C
Participation in an investigational drug or device study within 30 days prior to screening
There are over the counter medications that are not permitted during the study participation, the study coordinator will discuss the list during the screening process.
Content Validation of PROMIS 8a and the Development of an Instrument to Measure Drainage in Hidradenitis Suppurativa (HS)
The purpose of this study is to investigate the use and effectiveness of fatigue and drainage measurement tools for patients with hidradenitis suppurativa (HS). Participants will complete either an interview through Zoom or an online questionnaire.
Participants in this study will either complete an interview through Zoom or an online questionnaire to talk about their experiences with hidradenitis suppurativa fatigue and drainage.
Experienced fatigue as a result of your HS
Fluent in English
A Multicenter, Open-Label, Single Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.
Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.
Study coordinator will discuss.
Diagnosed with Moderate to Severe Atopic Dermatitis
Willing to attend all study visits and follow directions
Had a documented asthma exacerbation requiring hospitalization in the past 12 months.
Weigh less than 22 pounds
A 12-Week Double-Blind, Placebo-Controlled Randomized Phase 2 Trial with a 12-Week Open-Label Extension to Determine the Immunomodulatory Activity of PTM-001 in Patients with Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS): Assigned to PTM-001 (400mg) or placebo (no active ingredients) for 12 weeks after which all patients will receive the actual study medication, PTM-001 400mg daily for an additional 12 weeks. Males/Females 18 years of age and older.The goal of the study is assess the effect of PTM-001 on skin protein levels.
Agrees to follow all study directions
Positive for TB, HIV, Hepatitis B or Hepatitis C
Certain medications not allowed; study coordinator will discuss
For females: Pregnant, nursing or considering becoming pregnant
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis
Atopic Dermatitis (AD): Phase 3 double-blinded study, 8 week study with 44 week long-term safety period with guaranteed study medicine. Topical cream. Male and females ≥ 2 Years to < 12 Years with ADAtopic Dermatitis (AD), also known as eczema, is an inflammatory skin condition that can reoccur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up. The purpose of this study is to find out of the study medicine, ruxolitinib cream, can help with the treatment of AD.
Participants in this research study will need to return to the research site for up to 17 visits over 61 weeks. At this visits, participants will be asked to complete questionnaires, undergo blood draws, complete photography, and undergo physical and skin exams.
Up to $850.00
AD covering between 3% and 20% body surface
Willing to follow all study guidelines
Positive for Hepatitis B, Hepatitis C, or HIV
Previous treatment with JAK inhibitors
Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa
Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.
Eligible participants will attend a one time in person visit. During the visit, the study team will ask you to participate in the following activities: collect skin sample, blood sample and cheek swab. Take photographs of your HS lesions.
study coordinator will discuss.
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
An Open-label Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadaticinib in Pediatric Subjects with Severe Atopic Dermatitis
Phase 1, multiple-dose, open-label study consisting oftwo parts, male and female subjects aged 2 to 12 years with severe atopic dermatitis (eczema).
Have a diagnosis of Atopic Dermatitis for at least 6 months
No active Hep A, Hep C or Hep B
Current participation in another clinical trial
Reliability and Validity Testing of the Internalized Skin Bias Questionnaire – Revised
Studies have show that patients with skin conditions are often subject to social stigma. Exposure to these negative biases can lead to negative feelings for the patient. This study seeks to evaluate how patients with various skin conditions are impacted by these social biases.
Take an online survey that is expected to take 15-20 minutes. You will be asked to provide your email and take a short (5-10 minute) survey with some of the same questions 72 hours later.
Access to the internet
Must have a skin condition (Hidradenitis Suppurativa, Acne, Psoriasis, Atopic Dermatitis (Eczema), Vitiligo, Cutaneous lupus erythematosus, Rosacea, etc.)
Read/write in English
Those unable to consent
Those without a skin condition
Unable to read/write in English
A randomized, subject and investigator blinded, placebo controlledand multi-center platform study, to assessefficacy and safety of different investigational drugs inpatients with moderate to severe hidradenitis suppurativa
Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 7 and a half month study. Platform Study: Injectable and Oral drug, Males/Females 18-65 years old with Hidradenitis Suppurativa. Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area. The purpose of the study is to find out if the study drugs (iscalimab and LYS006) are beneficial and safe in patients with HS.
For this study there are up to 11 visits over a period of 6 months. Subjects will take an oral medication twice a day for 16 weeks and will come to the study site for questionnaires, physical exams, EKGs, blood draws, and urine testing at multiple visits.
Up to $500.00
HS lesions in at least 2 affected areas
A randomized, double blind, vehicle-controlled, multicenter Phase II study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of moderate to severe Acne vulgaris in adults with photodynamic therapy (PDT)
Moderate to Severe Acne Vulgaris: Males/Females 16 years and older. You will receive the study drug with either 1 hour or 3 hours between study drug application and illumination. The purpose of this study is to test the effectiveness and safety of the study drug, used at two different incubation times (time starting with administration of study drug until start of the red light illumination).
Subjects will attend in person visits in the Dermatology Clinical Trial Office. Your length of participation will depend on how your acne responds to the first treatment; the length of participation for 3 treatments will be approximately 25 weeks.Throughout the study at different time points Dr. Zaenglein will evaluate your acne, blood will be drawn, photos will be taken, and questionnaires will need to be completed.
Study Coordinator will discuss during phone screen.
willingness to stop topical facial treatments other than medical cleansers at least 14 days prior to receiving investigational product.
For females must use an adequate and highly effective or two effective methods of contraception throughout the study. Study coordinator will discuss.
For males- beard or other facial hair that might interfere with the study assessments unless subject agrees to be clean-shaven throughout the entire study period.
Certain medications/treatments not allowed during the study; study coordinator will discuss.
A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER COMPARATIVE EFFECTIVENESS STUDY OF SPIRONOLACTONE VERSUS DOXYCYCLINE HYCLATE FOR THE TREATMENT OF ACNE IN WOMEN
Mild to Severe Acne: Women ages 16-40 years. Assigned to either spironolactone of doxycycline; oral medication taken once daily. The duration of the study will last 16 weeks. During that time participants will attend 3 in person study visits (study start, week 8 and week 16). In addition participants will completion questions outside of study visits at Week 4 and Week 12. The goal of this trial is to compare the effectiveness of spironolactone and doxycycline hyclate in the treatment of acne in women.
The duration of the study will last 16 weeks. During that time participants will attend 3 in person study visits (study start, week 8 and week 16). In addition participants will completion questions outside of study visits at Week 4 and Week 12.
Birth control options will be discussed by study coordinator
Certain medical history conditions are not allowed; study coordinator will discuss
Assessing the treatment of scalp conditions in adult patients
This study is aiming to identify the differences in medicated hair care practices amongst adult patients with scalp conditions. Typical treatment for scalp conditions involves the continued use of medicated shampoos; however, hair care practices across all ethnic and racial barriers are different. This could impact the effectiveness of these medicated washes if they are by chance not being used frequently enough. To our knowledge, no research has explored hair care practices and their relationship to dermatological conditions that affect the scalp.
Participants will complete a one-time survey that will take approximately 5-10 minutes.
Access to email and internet
Have sebhorreic dermatitis, sebopsoriasis, dandruff, or psoriasis of the scalp
Any scalp conditions with open wounds or sores
A 2-Part Seamless Part A (phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)
SLE/CLE Lupus: 18 years and older; SC (subcutaneous injection) every 4 weeks with an additional dose given at Week 2 and Week 26. Randomization is 2:1 BIIB059 to placebo (non active ingredient); 52 weeks of treatment. There are 2 parts to the study, Part A and Part B. The goal of Part A is to confirm the adequacy of an investigator specific evaluation. The goal of Part B is to demonstrate the efficacy and safety of BIIB059 compared with placebo.
You will attend 21 visits and have 2 phone calls over approximately 52 weeks. At different time points throughout the study you will have photographs taken of your lesions, labs drawn, an ECG performed, skin examinations, a chest x-ray, you will need to complete questions, and fill out a diary.
Previous use and failure of antimalarial agents; study coordinator will discuss further
Certain medications not allowed; study coordinator will discuss
Certain medical history may be excluded from participation; study coordinator will discuss
Assessing the impact of post-inflammatory hyperpigmentation on quality of life in people of color
This survey study is looking to see how post-inflammatory hyperpigmentation (PIH) affects quality of life in people with skin of color.
Participants will complete a one-time survey that will ask about post-inflammatory hyperpigmentation.
Experienced/experiencing post-inflammatory hyperpigmentation
Individuals who are not able to understand English
Skin pathophysiology of Hidradenitis Suppurativa
The purpose of this research study is to collect skin samples from volunteers with HS and volunteers with healthy skin. The collected skin samples will be processed and compared to each other to see if there are specific differences in the skin between the HS volunteer group and the healthy skin volunteer group.
Participants will need to come to a one-time, in-person visit where biopsies (small skin samples) will be collected.- For participants with HS: Up to 4 biopsies will be collected - For participants with healthy skin: Up to 2 biopsies will be collected
HS lesions present in the armpits and/or groin
Certain medications are not allowed in this study- the study team will provide details
A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa
Site For AbbVie- HS Surgery
Must be diagnosed with HS for 1 year prior to study participation
Must be willing to perform self injections at home
Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa
Explore all stages of Hidradenitis Suppurativa with a topical medication.
There will be 7 in-person visits and 1 follow-up phone call over a 33 week period. Over the course of the study, the following study procedures will take place: medical history and medication history collection, ECG, lab tests (both blood and urine), photography, skin exams, physical exams, questionnaires, and skin biopsies.
Up to $350
Must have active HS in at least 1 area
Must have negative TB screening assessment
Certain medications can be continued if on stable dose; study coordinator will discuss further.
Pregnant (or considering becoming pregnant) or lactating females
Does not have reliable internet access for weekly electronic surveys
Incidence Rates of Hair Loss in Women Who Wear Hijab
The aim of this study is to obtain information regarding the incidence of hair-related concerns in women who wear hijab and to collect information pertaining to factors that could contribute to hair loss in women who wear the hijab.
This survey study will involve a one-time survey that will take 5-10 minutes.
Read and understand English
Ages 18 years and older